Oxytocin administration enhances controlled social cognition in patients with schizophrenia

Abstract

Summary Background Individuals with schizophrenia have functionally significant deficits in automatic and controlled social cognition, but no currently available pharmacologic treatments reduce these deficits. The neuropeptide oxytocin has multiple prosocial effects when administered intranasally in humans and there is growing interest in its therapeutic potential in schizophrenia. Methods We administered 40 IU of oxytocin and saline placebo intranasally to 29 male subjects with schizophrenia and 31 age-matched, healthy controls in a randomized, double-blind, placebo-controlled, cross-over study. Social cognition was assessed with The Awareness of Social Inference Test (TASIT) and the Reading the Mind in the Eyes Test (RMET). We examined the effects of oxytocin administration on automatic social cognition (the ability to rapidly interpret and understand emotional cues from the voice, face, and body); controlled social cognition (the ability to comprehend indirectly expressed emotions, thoughts, and intentions through complex deliberations over longer time periods); and a control task (the ability to comprehend truthful dialog and perform general task procedures) in individuals with and without schizophrenia using mixed factorial analysis of variance models. Results Patients with schizophrenia showed significant impairments in automatic and controlled social cognition compared to healthy controls, and administration of oxytocin significantly improved their controlled, but not automatic, social cognition, F(1, 58) = 8.75; p = 0.004. Conversely, oxytocin administration had limited effects on social cognition in healthy participants. Patients and controls performed equally well and there were no effects of oxytocin administration on the control task. Discussion Intact social cognitive abilities are associated with better functional outcomes in individuals with schizophrenia. Our data highlight the potentially complex effects of oxytocin on some but not all aspects of social cognition, and support the exploration of intranasal oxytocin as a potential adjunct treatment to improve controlled social cognition in schizophrenia. Published by Elsevier Ltd.

Intranasal Drug Delivery in Neuropsychiatry: Focus on Intranasal Ketamine for Refractory Depression

“…22,23 There has been much investigation of the possible benefits of intranasal oxytocin for schizophrenia, 24 with improvements recorded in domains such as clinical symptom ratings 25 and social cognition. 26 Intranasal oxytocin has also been studied for autism. For example, 15 children and adolescents with autism spectrum disorder showed improvement during 12 weeks of treatment in the domains of social functioning, repetitive behaviors, and anxiety; some improvements persisted as long as 3 months later.…”

Oxytocin Receptor <b><i>(OXTR)</i></b> Methylation and Cognition in Psychotic Disorders

“…Within psychotic disorders such as schizophrenia, broad cognitive deficits have been well documented [5,6,7,8], and oxytocin abnormalities may contribute to these deficits. Further, the link between social cognition and oxytocin in psychotic disorders has garnered attention due to treatment implications (e.g., intranasal oxytocin may improve facial emotion recognition) [9,10,11]. Recent evidence suggests that intranasal oxytocin may also improve general cognition in schizophrenia [12,13,14,15].…”

Oxytocin and social cognition in patients with schizophrenia: comparison with healthy siblings and healthy controls

“…This particular effect of the administration of intranasal OT on highlevel social cognition in SCH has been found independently by other groups [17] and remains significant after doubling sample size [18]. A recent study found that increases in key paternal parenting behaviours (e.g.…”